Join the club for FREE to access the whole archive and other member benefits.

Korro Bio

RNA editing, leveraging natural processes common to all multi-cellular organisms, merged with Frequency Therapeutics

Korro Bio is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and highly prevalent diseases. RNA editing is a natural physiological process that occurs in cells, including a mechanism mediated by an enzyme called Adenosine Deaminase Acting on RNA (ADAR). Korro Bio’s RNA editing approach involves co-opting this endogenous editing system via a proprietary engineered oligonucleotide to introduce precise edits to RNA. This unique technology enables the development of therapeutic candidates that deliver the functional benefits of gene therapy with a transient, titratable and specific treatment regimen, offering the potential to advance genetic medicines beyond rare genetic diseases into larger patient populations with common diseases. 

Korro Bio merged with Frequency Therapeutics on Jul 14th 2023.

Visit website:



Details last updated 26-Dec-2019

People at Korro Bio

Chris Loose

Co-founder and Chief Scientific Officer at Frequency Therapeutics

David Lucchino

Co-founder, President and CEO at Frequency Therapeutics.

Korro Bio News

Longevity Technology interviews Frequency Tx' CSO about activating innate progenitor cells

Longevity Technology - 01-Nov-2022

Cells are already in the right place, just need the right kick to help repair the body when needed


Hearing loss drug triggers improvements in phase 1/2 trials

FierceBiotech - 09-Apr-2019

Restoring hearing and vision would make many people's lives significantly easier

Topics mentioned on this page:
Regenerative Medicine, Hearing Loss